Необходима ли сегодня вакцинация против коронавирусной инфекции?
https://doi.org/10.22625/2072-6732-2023-15-3-5-14
Аннотация
Всемирная организация здравоохранения 4 мая 2023 г. объявила о том, что коронавирусная инфекция больше не является чрезвычайной ситуацией, но несмотря на это, предложила стратегический план обеспечения готовности и реагирования в связи с COVID-19 на 2023–2025 гг., который предусматривает определение каждой страной тактики иммунизации, регистрацию случаев заражения, надзор за возбудителем. В обзорной статье представлены данные по группам риска тяжелого течения новой коронавирусной инфекции, эффективности вакцинации в зависимости от наличия факторов риска у привитых и циркулирующего штамма вируса, а также подходы к вакцинации и ревакцинации против SARS-CoV-2, рекомендованные в настоящее время в мире.
Об авторах
К. К. Тихомирова
Детский научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Конфликт интересов:
Россия
Тихомирова Ксения Кирилловна – аспирант отдела вакцинопрофилактики и поствакцинальной патологии ДНКЦИБ; старший медицинский лаборант кафедры инфекционных заболеваний у детей ФП и ДПО СПбГПМУ.
Санкт-Петербург
тел.: 8(812)234-68-55
Конфликт интересов:
Нет
С. М. Харит
Детский научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Конфликт интересов:
Россия
Харит Сусанна Михайловна – руководитель научно-исследовательского отдела вакцинопрофилактики и поствакцинальной патологии ДНКЦИБ; профессор кафедры инфекционных заболеваний у детей ФП и ДПО СПбГПМУ, доктор медицинских наук, профессор.
Санкт-Петербург
тел.: 8(812)234-68-55
Конфликт интересов:
Нет
Список литературы
1. World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic.05 May 2023. [Internet], Available from: https://www.who.int/ru/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Internet], Available from: https://covid19.who.int/
3. World Health Organization. (2023). COVID-19 weekly epidemiological update, Edition 153 published 27 July 2023. World Health Organization. [Internet], Available from: https://apps.who.int/iris/handle/10665/369373
4. Сравнение показателей инфекционных заболеваний на интернет ресурсе I-Monitoring, [Интернет], доступно: https://www.iminfin.ru/areas-of-analysis/health/perechen-zabolevanij?territory=40000000
5. Эпидемиологическая обстановка и распространение COVID-19 в мире по состоянию на 8.00 по мск от 23.07.2023 г по данным ФКУН РосНИПЧИ «Микроб» [Интернет], доступно https://www.rospotrebnadzor.ru/region/korono_virus/epid.php
6. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2021 году: Государственный доклад, 01.06.2022 [Интернет], доступно: https://www.rospotrebnadzor.ru/upload/iblock/594/sqywwl4tg5arqff6xvl5dss0l7vvuank/Gosudarstvennyy-doklad.-O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsii-v-2021-godu.pdf
7. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: Государственный доклад, 01.06.2023 [Интернет], доступно: https://www.rospotrebnadzor.ru/bitrix/redirect.php?event1=file&event2=download&event3=GD-SEB.pdf&goto=/upload/iblock/b50/t4kqksh4b12a2iwjnha29922vu7naki5/GDSEB.pdf
8. World Health Organization. WHO Health Emergency Dashboard. [Internet]. Available from: https://covid19.who.int/region/euro/country/ru
9. Msemburi W, Karlinsky A, Knutson V, et al. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023 Jan;613(7942):130-137. doi: 10.1038/s41586-022-05522-2.
10. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020 Apr;92(4):441-447. doi: 10.1002/jmv.25689.
11. Щелканов, М.Ю. COVID-19: этиология, клиника, лечение / М.Ю. Щелканов [и др.] // Инфекция и иммунитет. – 2020. – Т. 10, №3. – C. 421–445. doi: 10.15789/2220-7619-CEC-1473.
12. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8.
13. Р.C. Y. Woo, R. J. de Groot , B.Haagmans, S. K. P. Lau, B. W. Neuman , S. Perlman , I.Sola , Lia van der Hoek , A. C. P. Wong, Shiou-Hwei Yeh (2023):ICTV Virus Taxonomy Profile: Corona-viridae 2023, Journal of General Virology (in press) https://ictv.global/report/chapter/coronaviridae/coronaviridae
14. Hoffmann M., Kleine-Weber H., Krüger N., et al. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020 Jan;31.929042 doi: 10.1101/2020.01.31.929042.
15. Graham MS, Sudre CH, May A, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-e345. doi: 10.1016/S2468-2667(21)00055-4.
16. World Health Organization. Tracking SARS-CoV-2 variants. [Internet], Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
17. Yamasoba D, Uriu K, Plianchaisuk A, et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant. Lancet Infect Dis. 2023 Jun;23(6):655-656. doi: 10.1016/S1473-3099(23)00278-5.
18. Karyakarte RP, Das R, Rajmane MV, Dudhate S, Agarasen J, et al. Chasing SARS-CoV-2 XBB.1.16 Recombinant Lineage in India and the Clinical Profile of XBB.1.16 Cases in Maharashtra, India. Cureus. 2023 Jun 1;15(6):e39816. doi: 10.7759/cureus.39816. PMID: 37397651; PMCID: PMC10314318.
19. О.Cóbar, S. Cóbar. Omicron Variants World Prevalence, 150 WHO Weekly Epidemiological Update and CDC COVID Data Tracker Review, Preprint · July 2023 DOI: 10.13140/RG.2.2.27620.35209),
20. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
21. Hu FH, Jia YJ, Zhao DY, et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Clin Microbiol Infect. 2023 Jul;29(7):835-844. doi: 10.1016/j.cmi.2023.03.017.
22. Varatharaj A, Thomas N, Ellul MA, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020 Oct;7(10):875-882. doi: 10.1016/S2215-0366(20)30287-X.
23. Быстрицкая, Е.В. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015–2019) / Е.В. Быстрицкая, Т.Н. Биличенко // Пульмонология. – 2021. – Т. 31, №. 5. – С. 551–561.
24. S. L. Shein, .C.L. Carroll, .K. E. Remy, C. M. Rogerson, . C. K. McCluskey, A. Lin, A.T. Rotta, Epidemiology and Outcome s of SARS-CoV-2 Infection or Multisystem Inflammatory Syndrome in Children vs Influenza Among Critically Ill Children JAMA Network Open. 2022;5(6):e2217217. doi:10.1001/jamanetworkopen.2022.17217
25. Nguyen NN, Houhamdi L, Hoang VT, et al. High rate of reinfection with the SARS-CoV-2 Omicron variant. J Infect. 2022 Aug;85(2):174-211. doi: 10.1016/j.jinf.2022.04.034.
26. Rodríguez-Grande C, Estévez A, Palomino-Cabrera R, et al. Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain. Emerg Infect Dis. 2023 Jun;29 (6):1154-1161. doi: 10.3201/eid2906.221696
27. R. Miyahara, K. Otani, T. Kamigaki, Y. Arima, M. Suzuki, K. Tamura, M. Nakazaki, H. Tani, K. Oishi, T. Kato, Y.K. Ko, SARS-CoV-2 Variants and Age-Dependent Infection Rates among Household and Nonhousehold Contacts Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 29, No. 8, August 2023, р.1648-50 DOI: https://doi.org/10.3201/eid2908.221582
28. Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Updated December 16, 2022. [Internet] Available from https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html
29. Временные методические рекомендации МЗ РФ «Медицинская реабилитация при новой коронавирусной инфекции (COVID-19)», версия 3, 01.11.2022 [Интернет] доступно https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/202/original/%D0%92%D0%9A%D0%A0_%D0%9C%D0%A0_COVID_19%D0%B2%D0%B5%D1%80%D1%81%D0%B8%D1%8F_07112022_%D0%B1%D0%B5%D0%B7_%D0%BF%D1%80%D0%B0%D0%B2%D0%BE%D0%BA.pdf?1669800267
30. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021 Aug 9;11(1):16144. doi: 10.1038/s41598-021-95565-8.
31. DeVries A, Shambhu S, Sloop S, Overhage JM. One-Year Adverse Outcomes Among US Adults With Post-COVID-19 Condition vs Those Without COVID-19 in a Large Commercial Insurance Database. JAMA Health Forum. 2023 Mar 3;4(3):e230010. doi: 10.1001/jamahealthforum.2023.0010.
32. Trapani G, Verlato G, Bertino E, et al. Long COVID-19 in children: an Italian cohort study. Ital J Pediatr. 2022 Jun 3;48(1):83. doi: 10.1186/s13052-022-01282-x.
33. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021 Mar;110(3):914-921. doi: 10.1111/apa.15673.
34. Osmanov IM, Spiridonova E, Bobkova P et al. Risk factors for post-COVID-19 condition in previously hospitalized children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J. 2022 Feb 3;59(2):2101341. doi: 10.1183/13993003.01341-2021.
35. Steenblock C, Schwarz PEH, Ludwig B, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021 Nov;9(11):786-798. doi: 10.1016/S2213-8587(21)00244-8.
36. Muniangi-Muhitu H, Akalestou E, Salem V, et al. Covid-19 and Diabetes: A Complex Bidirectional Relationship. Front Endocrinol (Lausanne). 2020 Oct 8;11:582936. doi: 10.3389/fendo.2020.582936.
37. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022 Apr 6;377:e069590. doi: 10.1136/bmj-2021-069590.
38. Douillet D, Riou J, Penaloza A, et al. Risk of symptomatic venous thromboembolism in mild and moderate COVID-19: A comparison of two prospective European cohorts. Thromb Res. 2021 Dec;208:4-10. doi: 10.1016/j.thromres.2021.10.001.
39. J. DeCuir, D.Surie, Y. Zhu, et al Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19– Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period – IVY Network,19 U.S. States, February 1, 2022–January 31, 2023 MMWR / April 28, 2023 / Vol. 72 / No. 17,р 463-468.
40. Khunti K, Valabhji J, Misra S. Diabetes and the COVID-19 pandemic. Diabetologia. 2023 Feb;66(2):255-266. doi: 10.1007/s00125-022-05833-z.
41. Wong MK, Brooks DJ, Ikejezie J, et al. COVID-19 Mortality and Progress Toward Vaccinating Older Adults – World Health Organization, Worldwide, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):113-118. doi: 10.15585/mmwr.mm7205a1.
42. Riou M, Marcot C, Canuet M, et al. Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study. Respir Med Res. 2021 May;79:100801. doi: 10.1016/j.resmer.2020.100801.
43. Singh AK, Gillies CL, Singh R, et al. Prevalence of comorbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab. 2020 Oct;22(10):1915-1924. doi: 10.1111/dom.14124.
44. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020 Jun 20;395(10241):1919-1926. doi: 10.1016/S0140-6736(20)31173-9. Epub 2020 May 28. Erratum in: Lancet. 2020 Aug 22;396(10250):534.
45. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020 Jun 20;395(10241):1907-1918. doi: 10.1016/S0140-6736(20)31187-9.
46. Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021 Jan 27;72(2):340-350. doi: 10.1093/cid/ciaa863.
47. World Health Organization. WHO COVID-19 Vaccine Tracker and Landscape. [Internet]. Available from: https://covid19.trackvaccines.org/
48. Our world in data [Internet]. Available from: https://ourworldindata.org/covid-vaccinations
49. Rahmani K, Shavaleh R, Forouhi M, et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Front Public Health. 2022 Aug 26;10:873596. doi: 10.3389/fpubh.2022.873596.
50. Zeng B, Gao L, Zhou Q, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med. 2022 May 23;20(1):200. doi: 10.1186/s12916-022-02397-y.
51. Balkan İİ, Dinc HO, Can G, et al. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required. Ir J Med Sci. 2023 Feb;192(1):19-25. doi: 10.1007/s11845-022-02984-1.
52. World Health Organization. (2023). COVID-19 weekly epidemiological update, edition 134, 16 March 2023. [Internet]. Available from: https://apps.who.int/iris/handle/10665/366534
53. Wang L, Kaelber DC, Xu R, Berger NA. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. Blood Rev. 2022 Jul;54:100931. doi: 10.1016/j.blre.2022.100931.
54. Mattiuzzi C, Lippi G. Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly. Vaccines (Basel). 2023 Jan 18;11(2):213. doi: 10.3390/vaccines11020213.
55. Smits PD, Gratzl S, Simonov M, et al. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. doi: 10.1016/j.vaccine.2023.02.038.
56. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members – Chicago, Illinois, December 2020-March 2021. Am J Transplant. 2021 Jun;21(6):2290-2297. doi: 10.1111/ajt.16634.
57. Maltezou HC, Gamaletsou MN, Giannouchos TV, et al. Timing of last COVID-19 vaccine dose and SARS-CoV-2 break-through infections in fully (boosted) vaccinated healthcare personnel. J Hosp Infect. 2023 Feb;132:46-51. doi: 10.1016/j.jhin.2022.11.016.
58. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845-1854. doi: 10.1016/S0140-6736(20)31208-3.
59. Spinardi JR, Srivastava A. Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines. Biomedicines. 2023 Jan 27;11(2):370. doi: 10.3390/biomedicines11020370.
60. González S, Olszevicki S, Salazar M, et al. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. EClinicalMedicine. 2021 Oct;40:101126. doi: 10.1016/j.eclinm.2021.101126.
61. Vokó Z, Kiss Z, Surján G, Surján O, et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUNVE study. Clin Microbiol Infect. 2022 Mar;28(3):398-404. doi: 10.1016/j.cmi.2021.11.011.
62. Shkoda, A.S.; Gushchin, V.A.; Ogarkova, D.A.; Stavitskaya, S.V.; Orlova, O.E.; Kuznetsova, N.A.; Keruntu, E.N.; Pochtovyi, A.A.; Pukhov, A.V.; Kleymenov, D.A.; et al. Sputnik V Effectiveness against Hospitalization with COVID-19 during Omicron Dominance. Vaccines 2022, 10, 938. https://doi.org/10.3390/vaccines10060938
63. Annex: Statement on the antigen composition of COVID-19 vaccines. 18 May 2023. [Internet]. Available from: https://www.who.int/docs/default-source/coronaviruse/tag-co-vacannex-may-2023_final_18052023.pdf?sfvrsn=59fee9ec_2
64. World Health Organization. SAGE updates COVID-19 vaccination guidance. 28 March 2023. [Internet]. Available from: https://www.who.int/news/item/28-03-2023-sage-updates-covid-19-vaccination-guidance
Рецензия
Для цитирования:
Тихомирова К.К., Харит С.М. Необходима ли сегодня вакцинация против коронавирусной инфекции? Журнал инфектологии. 2023;15(3):5-14. https://doi.org/10.22625/2072-6732-2023-15-3-5-14
For citation:
Tikhomirova K.K., Kharit S.M. Do we need coronavirus vaccination today? Journal Infectology. 2023;15(3):5-14. (In Russ.) https://doi.org/10.22625/2072-6732-2023-15-3-5-14
Просмотров:
510
.png)
.png)
Послать статью по эл. почте 